• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • J. Piccini, B. Hammill, +5 authors L. Curtis
  • Medicine
  • Circulation. Cardiovascular quality and outcomes
  • 2012 (First Publication: 1 January 2012)
  • Background— Atrial fibrillation (AF) is a common and costly problem among older persons. The frequency of AF increases with age, but representative national data about incidence and prevalence areExpand
  • K. Fox, J. Piccini, +9 authors R. Califf
  • Medicine
  • European heart journal
  • 2011 (First Publication: 1 October 2011)
  • AIMS Patients with non-valvular atrial fibrillation (AF) and renal insufficiency are at increased risk for ischaemic stroke and bleeding during anticoagulation. Rivaroxaban, an oral, direct factor XaExpand
  • Hein Heidbuchel, Peter Verhamme, +26 authors Bulent Gorenek
  • Medicine
  • European heart journal
  • 2017 (First Publication: 9 June 2016)
  • In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, VerhammeExpand
  • Benjamin A Steinberg, Peter Shrader, +10 authors Jonathan P Piccini
  • Medicine
  • Journal of the American College of Cardiology
  • 2016 (First Publication: 20 December 2016)
  • BACKGROUND Although non-vitamin K antagonist oral anticoagulants (NOACs) do not require frequent laboratory monitoring, each compound requires dose adjustments on the basis of certain clinicalExpand
  • S. Goodman, D. Wojdyla, +15 authors R. Califf
  • Medicine
  • Journal of the American College of Cardiology
  • 2014 (First Publication: 11 March 2014)
  • OBJECTIVES This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention ofExpand